Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030381 · ClinicalTrials.gov registry record · Phase 1
Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00030381: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00030381 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00030381, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Iododoxorubicin may dissolve protein deposits and be an effective treatment for primary systemic amyloidosis. Phase I trial to determine the effectiveness of iododoxorubicin in treating patients who have primary systemic amyloidosis
Interventions
- OTHER pharmacological study
- DRUG 4'-iodo-4'-deoxydoxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2001-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030381
The ClinicalTrials.gov registry entry for NCT00030381 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pharmacological study is the first listed.
NCT00030381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030381 about?
NCT00030381 is a clinical study titled "Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis". Iododoxorubicin may dissolve protein deposits and be an effective treatment for primary systemic amyloidosis. Phase I trial to determine the effectiveness of iododoxorubicin in treating patients who have primary systemic amyloidosis
What is the current status of trial NCT00030381?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2001-12.
What interventions are being tested in trial NCT00030381?
The interventions under investigation include: pharmacological study (OTHER), 4'-iodo-4'-deoxydoxorubicin (DRUG).
Who is sponsoring clinical trial NCT00030381?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.